Molecular Partners (NASDAQ:MOLN) Stock Price Up 7.1% – Here’s What Happened

Molecular Partners AG (NASDAQ:MOLN)’s stock price shot up 7.1% during trading on Monday . The company traded as high as $5.44 and last traded at $5.44. 2,138 shares changed hands during trading, a decline of 90% from the average session volume of 22,256 shares. The stock had previously closed at $5.08.

Analysts Set New Price Targets

Separately, Leerink Partnrs upgraded shares of Molecular Partners to a “strong-buy” rating in a research note on Monday, October 7th.

Molecular Partners Stock Up 7.1 %

The firm has a market capitalization of $219.57 million, a P/E ratio of -2.53 and a beta of 1.00. The firm has a 50 day moving average of $5.65 and a 200-day moving average of $5.94.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.